A. Tomé

Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19

Á. Soriano, F. Marco, José A. Martínez, 2021, Infectious Diseases and Therapy.

Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene

J. Yagüe, E. Ruíz-Ortiz, J. Antón, 2017, Front. Immunol..

Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center.

J. Yagüe, G. Espinosa, R. Cervera, 2016, Autoimmunity reviews.

Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study

Á. Soriano, J. Mallolas, M. Laguno, 2022, Infectious Diseases and Therapy.

Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients

Á. Soriano, J. Mallolas, M. Laguno, 2022, Infection.

C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19

Á. Soriano, J. Mallolas, M. Laguno, 2022, Scientific Reports.

Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

Felipe García, Á. Soriano, M. Laguno, 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

Á. Soriano, M. Laguno, J. Nicolás, 2020, medRxiv.